Purpose Although several reports have addressed cerebrospinal fluid (CSF) rhinorrhea
following dopamine agonist (DA) therapy of macroprolactinomas, further study is warranted …

Objective Prolactin-secreting tumors respond well to medical management, with a few
patients requiring surgery. We conducted a systematic review and meta-analysis to study the …

Integrative genomics approaches associating DNA structure and transcriptomic analysis
should allow the identification of cascades of events relating to tumor aggressiveness. While …

Simple Summary Prolactinomas constitute a subgroup of pituitary adenomas for which there
are several treatment options. Dopamine agonists (DA), since their introduction, have shown …

Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical
attention and are an important cause of hypogonadism and infertility. The ultimate goal of …

Context Surgical management of prolactinomas is an important treatment for patients
intolerant of dopamine agonist therapy. However, predictors of postoperative outcomes …

Prolactin-secreting tumors (prolactinomas) represent the most common pituitary tumor type,
accounting for 47–66% of functional pituitary tumors. Prolactinomas are usually benign and …

While prolactinoma patients have high bone turnover, current data are inconclusive when it
comes to determining whether correction of hyperprolactinemia and associated …

Changes in microRNAs (miRNAs) expression in many types of cancer suggest that they may
be involved in crucial steps during tumor progression. Indeed, miRNAs deregulation has …

The pituitary tumor-transforming gene (PTTG1) encodes a multifunctional protein (PTTG)
that is overexpressed in numerous tumours, including pituitary, thyroid, breast and ovarian …